Intact Vascular

52 articles about Intact Vascular

• Intact Vascular Announces Positive One-Year Data from TOBA II BTK Clinical Trial in VIVA Late-Breaking Session

  6/26/2020

  Durable Below-the-Knee Vascular Implant for Post-Angioplasty Dissection Repair Demonstrates Sustained Success Saving Limbs

• VIVA Late-Breaking Clinical Trial Session to Showcase TOBA II BTK One-Year Data

  6/22/2020

  Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the one-year data from its T ack O ptimized B alloon A ngioplasty (TOBA) II BTK clinical trial will be presented during the 2020 Vascular Interventional Advances (VIVA) Late-Breaking Clinical Trial event by Co-Principal Investigator, Patrick Geraghty, M.D., Professor of Surgery and Radio

• Intact Vascular Announces Publication of TOBA III Clinical Trial Results in the Journal of Vascular Surgery

  5/13/2020

  Peer-Reviewed Article Validates Tack Endovascular System ® as a Clinically Important Treatment for Post-Angioplasty Dissection Repair in Above-the-Knee Complex Lesions WAYNE, Pa.--( BUSINESS WIRE )-- Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the peer-reviewed publication of its T ack O ptimized B alloon A ngioplasty (TOBA) III 12-month clinical trial

• Intact Vascular Announces First U.S. Commercial Use of Tack Endovascular System® (4F) in Below-the-Knee Arteries

  4/22/2020

  Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the first commercial use of its Tack Endovascular System® (4F) in multiple sites across the United States.

• Tack Endovascular System® Receives FDA Approval for Below-the-Knee Post-Angioplasty Dissection Repair

  4/14/2020

  Intact Vascular’s Tack Endovascular System is a First-of-its-Kind Vascular Implant for Optimized Balloon Angioplasty Outcomes in Challenging CLI Patient Population

• Intact Vascular Announces Positive Six-Month Data from TOBA II BTK Clinical Trial During Late-Breaking Session at 2019 VIVA Conference

  11/6/2019

  First-of-its-Kind Pivotal Study of the Tack Endovascular System® Demonstrates 100% Dissection Resolution in Challenging Below-the-Knee Disease

• Journal of Endovascular Therapy Publishes Peer Reviewed Article Highlighting Real-World Use of the Tack Endovascular System®

  10/29/2019

  Study Demonstrates Safety and Efficacy of Intact Vascular’s Tack® Implants for Focal Dissection Repair in Complex Lesions

• Intact Vascular to Announce Six-Month Data from TOBA II BTK Clinical Trial

  10/22/2019

  First Pivotal Study to Investigate Permanent Vascular Implant as a Treatment for Post-Angioplasty Dissections in Arteries Below the Knee (BTK)

• Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

  9/27/2019

  Growing Body of Evidence Supporting Use of the Tack Endovascular System® to Improve Balloon Angioplasty Outcomes for Patients Suffering from PAD

• Intact Vascular to Announce One-Year Data from TOBA III Clinical Trial

  9/16/2019

  Study Investigates Use of the Tack Endovascular System® for Focal Dissection Repair Following Drug-Coated Balloon Angioplasty in PAD Patients

• Journal of Endovascular Therapy Publishes Peer Reviewed Article Underscoring the Clinical Impact of Post-Angioplasty Dissections

  6/18/2019

  Intact Vascular’s Tack Endovascular System® is highlighted as a treatment option for post-PTA dissections

• Intact Vascular Announces $25 Million Financing with Vensana Capital to Drive Commercialization of the Tack Endovascular System®

  5/29/2019

  Intact Vascular, Inc. announced a $25 million financing with Vensana Capital as the lead investor.

• Intact Vascular to Sponsor Post-Angioplasty Dissection Symposium at 2019 New Cardiovascular Horizons Conference

  5/20/2019

  Presentations Highlight the Tack Endovascular System® for Focal Dissection Repair Device Following Balloon Angioplasty

• Intact Vascular Announces US Launch of the Tack Endovascular System® and First Commercial Use

  5/6/2019

  Intact Vascular, Inc. announced the first commercial use of its Tack Endovascular System in multiple sites across the United States.

• Intact Vascular’s Tack Endovascular System® Receives FDA Approval

  4/15/2019

  First-of-its-Kind Treatment for Post-Angioplasty Above-the-Knee Dissections Now Available

• Intact Vascular Announces Presentations at LINC 2019 Annual Meeting

  1/14/2019

  ​Presentations Showcase the Importance of Treating Post-Angioplasty Dissections

• Intact Vascular Announces Launch of the Tack Endovascular System® in the EU and First Commercial Use in Germany

  1/7/2019

  The Tack® implant is a first-of-its kind device for patients with peripheral arterial disease and/or critical limb ischemia

• Intact Vascular Announces Enrollment Completion of TOBA II BTK Clinical Trial

  1/2/2019

  First-of-its-kind study designed to demonstrate safety and efficacy of the Tack Endovascular System® in treating post-PTA dissections below the knee

• Intact Vascular Hires Industry Veteran Steve MacKinnon as Vice President of Sales

  11/5/2018

  Reporting to the CEO, Mr. MacKinnon will oversee the creation of a U.S. based sales team and will play a central role in planning and executing the company’s projected launch of the Tack Endovascular System® in 2019.

• Intact Vascular Announces Presentation of TOBA II Pivotal Data

  10/8/2018

  Data to be presented as a Late-Breaking Clinical Trial at the 2018 VIVA Conference